Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial (Q40955003)
Jump to navigation
Jump to search
scientific article published on 9 June 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial |
scientific article published on 9 June 2016 |
Statements
1 reference
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial (English)
1 reference
Julio Rosenstock
1 reference
Michaela Diamant
1 reference
Vanita R Aroda
1 reference
Louise Silvestre
1 reference
Elisabeth Souhami
1 reference
Tianyue Zhou
1 reference
Riccardo Perfetti
1 reference
Vivian Fonseca
1 reference
LixiLan PoC Study Group
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference